Journal: Human Vaccines & Immunotherapeutics

Article Title: Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review

doi: 10.1080/21645515.2023.2167410

Figure Lengend Snippet: Highest and lowest reported vaccine effectiveness (VE, with 95% confidence intervals) values of the COVID-19 vaccines against the Omicron variant in reducing infection as compared to the Delta variant.

Article Snippet: Compared to boosting 5 months prior to testing, Pfizer/BioNTech booster-VE against Omicron infection decreased each month from vaccination, with a peak VE of 53.4% (95% CI: 47.7–58.6) for those boosted just a month prior to testing versus a VE of 3.6% (95% CI: 0.6–6.5) for those boosted 4 months prior to testing.

Techniques: Variant Assay, Infection

Journal: Human Vaccines & Immunotherapeutics

Article Title: Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review

doi: 10.1080/21645515.2023.2167410

Figure Lengend Snippet: Highest and lowest reported vaccine effectiveness (VE, with 95% confidence intervals) values of the COVID-19 vaccines against the Omicron variant in reducing hospitalization as compared to the Delta and Alpha variants.

Article Snippet: Compared to boosting 5 months prior to testing, Pfizer/BioNTech booster-VE against Omicron infection decreased each month from vaccination, with a peak VE of 53.4% (95% CI: 47.7–58.6) for those boosted just a month prior to testing versus a VE of 3.6% (95% CI: 0.6–6.5) for those boosted 4 months prior to testing.

Techniques: Variant Assay

Journal: Human Vaccines & Immunotherapeutics

Article Title: Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review

doi: 10.1080/21645515.2023.2167410

Figure Lengend Snippet: Highest and lowest reported vaccine effectiveness (VE, with 95% confidence intervals) values of the COVID-19 vaccines against the Omicron variant in reducing the severity of infection as compared to the Delta variant.

Article Snippet: Compared to boosting 5 months prior to testing, Pfizer/BioNTech booster-VE against Omicron infection decreased each month from vaccination, with a peak VE of 53.4% (95% CI: 47.7–58.6) for those boosted just a month prior to testing versus a VE of 3.6% (95% CI: 0.6–6.5) for those boosted 4 months prior to testing.

Techniques: Variant Assay, Infection

Journal: Human Vaccines & Immunotherapeutics

Article Title: Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review

doi: 10.1080/21645515.2023.2167410

Figure Lengend Snippet: Highest and lowest reported vaccine effectiveness (VE with 95% confidence intervals) values of the COVID-19 vaccines against the Omicron variant in reducing mortality as compared to the Delta variant.

Article Snippet: Compared to boosting 5 months prior to testing, Pfizer/BioNTech booster-VE against Omicron infection decreased each month from vaccination, with a peak VE of 53.4% (95% CI: 47.7–58.6) for those boosted just a month prior to testing versus a VE of 3.6% (95% CI: 0.6–6.5) for those boosted 4 months prior to testing.

Techniques: Variant Assay

Journal: Immunity, Inflammation and Disease

Article Title: Impaired immunity and high attack rates caused by SARS‐CoV‐2 variants among vaccinated long‐term care facility residents

doi: 10.1002/iid3.679

Figure Lengend Snippet: IgG levels to WT SARS‐CoV‐2 spike glycoprotein after vaccination with Comirnaty. (A) Receptor binding domain (RBD) and (B) full‐length spike glycoprotein (SFL) in binding antibody units (BAU)/ml. Dashed lines mark the threshold for positive result per antigen. Statistical significance measured with Wilcoxon rank‐sum test, significance level 0.05. IgG, immunoglobulin G; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.

Article Snippet: In a recent study we conducted in another nursing home, we observed that while 7/7 nursing home residents had NAb to Delta, 2/7 did not have measurable NAb to either Beta or Omicron variant despite receiving a Pfizer/BioNTech Comirnaty booster 21–42 days prior.

Techniques: Binding Assay

Journal: Immunity, Inflammation and Disease

Article Title: Impaired immunity and high attack rates caused by SARS‐CoV‐2 variants among vaccinated long‐term care facility residents

doi: 10.1002/iid3.679

Figure Lengend Snippet: Geometric mean neutralizing antibody (NAb) titers (GMT [95% CI]) to wild‐type (WT), Alpha and Beta variants of SARS‐CoV‐2 and anti‐spike IgG concentrations (GMC [95%CI]) expressed in binding antibody units/ml. Vaccinated and noninfected (PCR‐) with Pfizer/BioNTech Comirnaty, COVID‐19 outbreaks in long‐term care facilities (LTCFs), 2021, Finland

Article Snippet: In a recent study we conducted in another nursing home, we observed that while 7/7 nursing home residents had NAb to Delta, 2/7 did not have measurable NAb to either Beta or Omicron variant despite receiving a Pfizer/BioNTech Comirnaty booster 21–42 days prior.

Techniques: Binding Assay, Variant Assay

Journal: Immunity, Inflammation and Disease

Article Title: Impaired immunity and high attack rates caused by SARS‐CoV‐2 variants among vaccinated long‐term care facility residents

doi: 10.1002/iid3.679

Figure Lengend Snippet: Peripheral blood mononuclear cell (PBMC) responses to stimulation with (A) SARS‐CoV‐2 recombinant spike glycoprotein or (B) SARS‐CoV‐2 recombinant nucleoprotein. The secretion of IFN‐γ, perforin‐1 or granzyme B into supernatants was measured after 6 days in infected or noninfected residents and healthcare workers (HCWs,) who all had received two doses of Comirnaty. Cytokine concentrations are presented as stimulation indexes. Dashed line marks the threshold for a positive result (stimulation index ≥3). IFN, interferon; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus.

Article Snippet: In a recent study we conducted in another nursing home, we observed that while 7/7 nursing home residents had NAb to Delta, 2/7 did not have measurable NAb to either Beta or Omicron variant despite receiving a Pfizer/BioNTech Comirnaty booster 21–42 days prior.

Techniques: Recombinant, Infection

Journal: Annals of Medicine

Article Title: Neutralizing antibodies against SARS-CoV-2 of vaccinated healthcare workers in Taiwan

doi: 10.1080/07853890.2024.2442533

Figure Lengend Snippet: Neutralizing antibody levels between groups and post-vaccination days. Analysis of neutralizing antibody levels using the cPass SARS-CoV2 neutralizing antibody assay after 2 doses of vaccination. (A) Comparison of neutralizing antibody levels between 3 groups of participants who received the vaccine (1st and 2nd dose of vaccine combinations) from AstraZeneca (AZD1222) and Moderna (mRNA-1273) vaccines. (B) Longitudinal analysis of the correlation between neutralizing antibody levels and post-vaccination days who received the AZD1222 + AZD1222 vaccine group (blue color). (C). Longitudinal analysis of the correlation between neutralizing antibody levels and post-vaccination days who received the AZD1222 + mRNA-1273 vaccine group(green color). (D) Longitudinal analysis of the correlation between neutralizing antibody levels and post-vaccination days who received the mRNA-1273 + mRNA1273 vaccine group (red color). The difference in neutralizing antibody levels between groups was analyzed using the Kruskal-Wallis test (ns: not significant and **** p < 0.0001). Data were expressed as median and IQR. The Pearson correlation was used for the analysis of the correlation between neutralizing antibody levels and post-vaccination days.

Article Snippet: A study in Thailand with other mRNA vaccine boosters (Pfizer-BioNTech/BNT) also shows higher antibody levels than AZD1222 boosters in healthcare workers [ ].

Techniques: Comparison, Vaccines

Journal: Annals of Medicine

Article Title: Neutralizing antibodies against SARS-CoV-2 of vaccinated healthcare workers in Taiwan

doi: 10.1080/07853890.2024.2442533

Figure Lengend Snippet: Neutralizing antibody levels and age. Correlation of antibody levels and age, measured using cPass SARS-CoV-2 neutralizing antibody assay after 2 doses of vaccination with age: (A) AZD1222 + AZD1222 vaccine group (blue color). (B) AZD1222 + mRNA-1273 vaccine group (green color). (C) mRNA-1273 + mRNA-1273 vaccine group (red color). The Pearson correlation was used for the analysis of the correlation between neutralizing antibody levels and age.

Article Snippet: A study in Thailand with other mRNA vaccine boosters (Pfizer-BioNTech/BNT) also shows higher antibody levels than AZD1222 boosters in healthcare workers [ ].

Techniques: